{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-320150","form_type":"8-K","ticker":"NUVL","cik":"0001861560","company_name":"Nuvalent, Inc.","filed_at":"2025-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.860483+00:00","generated_at":"2026-05-16T13:05:42.536279+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Royalty Pharma buys 1.5% royalty on Nuvalent's pipeline for up to $315M","bullets":["Royalty Pharma acquired a preexisting 1.5% net-sales royalty on neladalkib and zidesamtinib from an undisclosed third party.","The deal value is up to $315 million; Nuvalent is not a party to the transaction.","Nuvalent clarifies the 'low single digit preexisting royalty' is exactly 1.5% of net sales of both candidates.","Nuvalent's revenue share agreement with its scientific founder remains unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-320150","json":"https://secwatch.observer/filing/0001193125-25-320150.json","markdown":"https://secwatch.observer/filing/0001193125-25-320150.md","text":"https://secwatch.observer/filing/0001193125-25-320150.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861560/000119312525320150/0001193125-25-320150-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861560/000119312525320150/d53736d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:05:42.536279+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}